A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Part of paid clinical trials in Fayetteville, Arkansas.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT00478634
- Phase
- PHASE1
- Status
- Completed
Conditions
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Tumors
- Neoplasms, Colorectal
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
Study Details
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Key Dates
- Start date
- May 31, 2007
- Status verified
- Nov 2012
- Primary completion
- Sep 30, 2009
- Completion
- Sep 30, 2009
Study Design
- Enrollment
- 19 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: A1: RAD001 + cetuximab + irinotecanRAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
- Experimental: B1 dose: RAD001 + cetuximab + irinotecanRAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
Primary Outcome Measure
Dose Limiting Toxicities [ Time Frame: at end of cycle 2 ]
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72701 | - |
| Comprehensive nBlood and Cancer Care | Bakersfield | California | 93309 | - |
| UCSD - Moores Cancer Center | La Jolla | California | 92037 | - |
| Comprehensive Cancer Care | Los Angeles | California | 90095 | - |
| North Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center | Northridge | California | 91325 | - |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 90277 | - |
| Norwalk Hospital | Norwalk | Connecticut | 06850 | - |
| Gerogetown University Lombardi Cancer Center | Washington D.C. | District of Columbia | 20057 | - |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| Oncology Specialists | Park Ridge | Illinois | 60068 | - |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | - |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | - |
| Richmond University Medical Center | Staten Island | New York | 10310 | - |
| UNC School of Medicine | Chapel Hill | North Carolina | 27599 | - |
| Oncology/Hematology Associates | Bethlehem | Pennsylvania | 18017 | - |
| Arlington Cancer Center | Arlington | Texas | 76012 | - |
Find similar trials in Fayetteville, AR
By condition
By specialty
By research site
Highlands Oncology Group· Fayetteville, ARComprehensive nBlood and Cancer Care· Bakersfield, CAUCSD - Moores Cancer Center· La Jolla, CAComprehensive Cancer Care· Los Angeles, CANorth Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center· Northridge, CACancer Care Associates Medical Group, Inc.· Redondo Beach, CA
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesPHASE1/PHASE2 · Recruiting · Anwaar Saeed · Westwood, Kansas
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas